Age: 10.0
Sex: F
Vaccine: HPV4
Symptoms: Skin discolouration, Somnolence, Syncope, Temperature intolerance, Tremor
Clinical narrative: postural orthostatic tachycardia (POTS)/ frequent headaches, nausea, chronic fatigue, lightheadedness, dizziness, fainting, racing heart and palpitations, chest pain, difficulty breathing, somnolence, difficulty sleeping/ sensitivity to heat; vision loss; chronic fatigue syndrome/ difficulty concentrating/ joint pain/ shooting pain in her calves and feet/ somnolence; autoimmune injuries; muscle weakness; This spontaneous report was received from a lawyer, regarding a case in litigation and refers to a female patient (pt), who was an adult at the time of report but whose age/age group at the time of events could not be established unequivocally. The patient's concurrent conditions, medical history and concomitant medications were not provided. On unknown dates, at the age of 10 years old, the patient was vaccinated with first, second and third dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL) (doses, routes of administrations, anatomical locations, lot # and expiry dates were not provided) for preventing cervical cancer, as recommended by physician and consented by patient's mother. On an unknown date, the pt sustained serious and debilitating injuries, including but not limited to autonomic, autoimmune, and neurological injuries and resulting sequelae as a result of receiving the quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) vaccine. On unknown dates, following her quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) injections, she experienced frequent headaches, nausea, chronic fatigue, lightheadedness, dizziness, fainting, racing heart and palpitations, chest pain, difficulty breathing, vision loss, somnolence, difficulty sleeping, muscle weakness, sensitivity to noise, light, and heat, overheating, joint pain, discoloration of her skin, shooting pains in her calves and feet, hand tremors, and difficulty concentrating. As the months progressed, so did the pt's symptoms. She was seen by multiple physicians and specialists for her complaints and was ultimately diagnosed with postural orthostatic tachycardia (POTS). She did not know and had no reason to know that the symptoms she was experiencing were caused by the quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) vaccine, as no information to the contrary was given to her by her medical providers. It was not until early 2023 that she began to suspect that quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) could be the cause of her symptoms and injuries. As a result of her post-quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) symptoms, she had been unable to engage in activities that a normal young person would enjoy. Post-quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) injections, her academic performance, extracurricular activities and dreams for the future had been negatively impacted. Based upon her chronic and severe post-quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) symptoms, the pt had been diagnosed with various medical conditions, including but not limited to, postural orthostatic tachycardia (POTS), dysautonomia, and chronic fatigue syndrome. As a proximate result of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL), the pt suffered and continued to suffer severe and permanent physical injuries, and associated symptomology and suffered severe and permanent emotional injuries, including pain and suffering. The pt also had a substantial fear of suffering additional and ongoing harms, including but not limited to being at an increased risk of cancer, and future symptoms and harms associated with her injuries caused by quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL). The outcome of the events was considered to be not recovered. The events were considered to be related to quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL).  Upon internal review, the events of vision loss and autoimmune injuries were considered to be medically significant. All events were determined to be disabling.